Main cardiologists imagine polypills might stop thousands and thousands of untimely deaths, coronary heart assaults and strokes.
In line with two main cardiologists in an announcement revealed in
“This systemic failure is a global tragedy, as many premature deaths from CVD could be avoided,” says Professor Salim Yusuf, Executive Director of the Population Health Research Institute (PHRI) and Professor Emeritus of Medicine at McMaster University.
Every year, about 54 million individuals suffer from cardiovascular disease; one-third of them die as a result of CVD, with 80 percent of them residing in low- and middle-income countries.
Most heart attacks and strokes occur in patients who have never had CVD, implying that primary prevention of the first heart attack or stroke is important. Secondary prevention is also important for individuals who already have CVD, although it does not have the same impact.
“The current strategy for primary and secondary prevention of CVD has only been modestly successful in most countries, including high-income countries. Even in these countries, fewer than half of patients with prior CVD, and fewer than 20% without prior CVD, receive effective preventive treatments,” says Professor Yusuf.
The polypill, also known as fixed-dose combination (FDC) therapy – with the combination of blood pressure lowering agents, a statin for lowering LDL cholesterol, and low-dose aspirin – was proposed in the early 2000s as a means to reduce CVD substantially and at low cost.
“The answer is now clear and resounding, with data from three independent, large, and long-term trials in primary prevention and one in secondary prevention showing its life-saving significance,” says Yusuf, whose various publications have shown that heart attacks and strokes were cut by 35 to 50 percent by using a polypill.
“It is time to use the polypill widely to save millions of lives each year,” says Professor Pinto. He and Professor Yusuf recommend the following new strategies:
- Encourage large pharmaceutical companies to invest in developing and testing polypills – in particular, newer polypills with larger blood pressure lower effects (such as combining low doses of 3 or 4 classes of drugs with statins and low doses of aspirin). Manufacturing with generic components, and marketing polypills at locally sensitive prices, would ensure affordability while maintaining profitability for the companies, thereby enhancing use by the majority of people around the world.
- Include polypills in the WHO’s Essential Medicines List, and in guidelines for both primary and secondary prevention of CVD is an important next step. “This would encourage governments and insurance companies, especially in low-income and middle-income countries to include in their formularies, and clinicians to recommend its use,” Pinto and Yusuf write.
- Combine the polypill with lifestyle advice for CVD prevention delivered by trained non-physician health workers (NPHWs) – not meant as a replacement for physicians who can use their advanced skills on managing individuals with more complex conditions – thus a combined strategy that would help many more people.
Reference: “The polypill: from concept and evidence to implementation” by Salim Yusuf and Fausto J Pinto, 12 October 2022, The Lancet.